Immunogenicity for 16 serotypes of a unique schedule of pneumococcal vaccines in a high-risk population

Amanda Leach; Peter Morris; Grant Mackenzie; J McDonnell; Anne Balloch; Jonathan Carapetis; Mimi Tang

Immunogenicity for 16 serotypes of a unique schedule of pneumococcal vaccines in a high-risk population

Amanda Leach, Peter Morris, Grant Mackenzie, J McDonnell, Anne Balloch, Jonathan Carapetis, Mimi Tang

Research output: Contribution to journal › Article › peer-review

Abstract

Background: A unique schedule of 7-valent pneumococcal conjugate vaccine (7PCV) at 2, 4 and 6 months of age and 23-valent pneumococcal polysaccharide vaccine (23PPV) at 18 months commenced for Australian Aboriginal infants in 2001. Methods: Anti-capsular IgG concentrations in vaccinated and non-vaccinated (historic control) infants were determined (blinded) by (22F absorbed) ELISA. Results: One month after dose 3 of 7PCV, geometric mean concentrations (GMCs) were >1.95 ?g/ml and at least 89% of infants had IgG >0.35 ?g/ml to all 7PCV serotypes. One month post-23PPV, IgG to 7PCV serotypes was >0.35 ?g/ml for more than 96% infants (>1.3 ?g/ml for at least 70%), and IgG to non-7PCV serotypes was >0.35 ?g/ml for more than 50% infants (including serotype 6A, but not 12F (17%) or 19A (44%). Conclusion: 7PCV and 23PPV are immunogenic in this population. � 2008 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	3885-3891
Number of pages	7
Journal	Vaccine
Volume	26
Issue number	31
Publication status	Published - 2008

Cite this

@article{c07d6797107149a79f39c3eb5c77ce9f,

title = "Immunogenicity for 16 serotypes of a unique schedule of pneumococcal vaccines in a high-risk population",

abstract = "Background: A unique schedule of 7-valent pneumococcal conjugate vaccine (7PCV) at 2, 4 and 6 months of age and 23-valent pneumococcal polysaccharide vaccine (23PPV) at 18 months commenced for Australian Aboriginal infants in 2001. Methods: Anti-capsular IgG concentrations in vaccinated and non-vaccinated (historic control) infants were determined (blinded) by (22F absorbed) ELISA. Results: One month after dose 3 of 7PCV, geometric mean concentrations (GMCs) were >1.95 ?g/ml and at least 89% of infants had IgG >0.35 ?g/ml to all 7PCV serotypes. One month post-23PPV, IgG to 7PCV serotypes was >0.35 ?g/ml for more than 96% infants (>1.3 ?g/ml for at least 70%), and IgG to non-7PCV serotypes was >0.35 ?g/ml for more than 50% infants (including serotype 6A, but not 12F (17%) or 19A (44%). Conclusion: 7PCV and 23PPV are immunogenic in this population. � 2008 Elsevier Ltd. All rights reserved.",

keywords = "immunoglobulin G antibody, Pneumococcus vaccine, article, Australia, controlled study, drug efficacy, enzyme linked immunosorbent assay, high risk population, human, immunogenicity, infant, otitis media, priority journal, serotype, Streptococcus infection, umbilical cord blood, vaccination, Antibodies, Bacterial, Bacterial Capsules, Enzyme-Linked Immunosorbent Assay, Humans, Immunization Schedule, Immunoglobulin G, Infant, Longitudinal Studies, Meningococcal Vaccines, Pneumococcal Infections, Pneumococcal Vaccines",

author = "Amanda Leach and Peter Morris and Grant Mackenzie and J McDonnell and Anne Balloch and Jonathan Carapetis and Mimi Tang",

year = "2008",

language = "English",

volume = "26",

pages = "3885--3891",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "31",

}

TY - JOUR

T1 - Immunogenicity for 16 serotypes of a unique schedule of pneumococcal vaccines in a high-risk population

AU - Leach, Amanda

AU - Morris, Peter

AU - Mackenzie, Grant

AU - McDonnell, J

AU - Balloch, Anne

AU - Carapetis, Jonathan

AU - Tang, Mimi

PY - 2008

Y1 - 2008

N2 - Background: A unique schedule of 7-valent pneumococcal conjugate vaccine (7PCV) at 2, 4 and 6 months of age and 23-valent pneumococcal polysaccharide vaccine (23PPV) at 18 months commenced for Australian Aboriginal infants in 2001. Methods: Anti-capsular IgG concentrations in vaccinated and non-vaccinated (historic control) infants were determined (blinded) by (22F absorbed) ELISA. Results: One month after dose 3 of 7PCV, geometric mean concentrations (GMCs) were >1.95 ?g/ml and at least 89% of infants had IgG >0.35 ?g/ml to all 7PCV serotypes. One month post-23PPV, IgG to 7PCV serotypes was >0.35 ?g/ml for more than 96% infants (>1.3 ?g/ml for at least 70%), and IgG to non-7PCV serotypes was >0.35 ?g/ml for more than 50% infants (including serotype 6A, but not 12F (17%) or 19A (44%). Conclusion: 7PCV and 23PPV are immunogenic in this population. � 2008 Elsevier Ltd. All rights reserved.

AB - Background: A unique schedule of 7-valent pneumococcal conjugate vaccine (7PCV) at 2, 4 and 6 months of age and 23-valent pneumococcal polysaccharide vaccine (23PPV) at 18 months commenced for Australian Aboriginal infants in 2001. Methods: Anti-capsular IgG concentrations in vaccinated and non-vaccinated (historic control) infants were determined (blinded) by (22F absorbed) ELISA. Results: One month after dose 3 of 7PCV, geometric mean concentrations (GMCs) were >1.95 ?g/ml and at least 89% of infants had IgG >0.35 ?g/ml to all 7PCV serotypes. One month post-23PPV, IgG to 7PCV serotypes was >0.35 ?g/ml for more than 96% infants (>1.3 ?g/ml for at least 70%), and IgG to non-7PCV serotypes was >0.35 ?g/ml for more than 50% infants (including serotype 6A, but not 12F (17%) or 19A (44%). Conclusion: 7PCV and 23PPV are immunogenic in this population. � 2008 Elsevier Ltd. All rights reserved.

KW - immunoglobulin G antibody

KW - Pneumococcus vaccine

KW - article

KW - Australia

KW - controlled study

KW - drug efficacy

KW - enzyme linked immunosorbent assay

KW - high risk population

KW - human

KW - immunogenicity

KW - infant

KW - otitis media

KW - priority journal

KW - serotype

KW - Streptococcus infection

KW - umbilical cord blood

KW - vaccination

KW - Antibodies, Bacterial

KW - Bacterial Capsules

KW - Enzyme-Linked Immunosorbent Assay

KW - Humans

KW - Immunization Schedule

KW - Immunoglobulin G

KW - Infant

KW - Longitudinal Studies

KW - Meningococcal Vaccines

KW - Pneumococcal Infections

KW - Pneumococcal Vaccines

M3 - Article

SN - 0264-410X

VL - 26

SP - 3885

EP - 3891

JO - Vaccine

JF - Vaccine

IS - 31

ER -

Immunogenicity for 16 serotypes of a unique schedule of pneumococcal vaccines in a high-risk population

Abstract

Fingerprint

Cite this